Cordis Corp. said that the results of the head-to-head clinical trial it funded pitting its Cypher drug-eluting stent against Boston Scientific Corp.'s Taxus stent found that Cypher was associated with the development of fewer blood clots. But the two fiercely competing stents -- the only drug-eluting stents on the U.S. market -- were equally deliverable and efficacious in preventing restenosis, or re-clogging of the coronary arteries, according to the study.
For its part, in a press release Boston Scientific said it welcomed the results, which "reaffirmed the safety and efficacy" of the Taxus even though the study "failed to meet its primary endpoint."
Results of the study were released at the meeting of the American College of Cardiology in Orlando, Fla. Sponsored by Cordis, a Johnson & Johnson company, the trial involved 1,386 patients at 90 hospitals in Asia, Europe and Latin America.